中枢神经系统疾病的 RNA 干扰治疗的最新进展。
Recent advances in RNA interference therapeutics for CNS diseases.
机构信息
Interdisciplinary program in Genetics, University of Iowa, Iowa City, IA 52242, USA.
出版信息
Neurotherapeutics. 2013 Jul;10(3):473-85. doi: 10.1007/s13311-013-0183-8.
Abstract
Over the last decade, RNA interference technology has shown therapeutic promise in rodent models of dominantly inherited brain diseases, including those caused by polyglutamine repeat expansions in the coding region of the affected gene. For some of these diseases, proof-of concept studies in model organisms have transitioned to safety testing in larger animal models, such as the nonhuman primate. Here, we review recent progress on RNA interference-based therapies in various model systems. We also highlight outstanding questions or concerns that have emerged as a result of an improved (and ever advancing) understanding of the technologies employed.
摘要
在过去的十年中，RNA 干扰技术在显性遗传性脑疾病的啮齿动物模型中显示出了治疗潜力，包括那些由受影响基因编码区的多聚谷氨酰胺重复扩展引起的疾病。对于其中一些疾病，在模式生物中进行的概念验证研究已经过渡到更大动物模型（如非人类灵长类动物）的安全性测试。在这里，我们回顾了各种模型系统中基于 RNA 干扰的治疗方法的最新进展。我们还强调了由于对所使用技术的理解（以及不断提高）而出现的一些悬而未决的问题或关注点。
相似文献
1
Recent advances in RNA interference therapeutics for CNS diseases.中枢神经系统疾病的 RNA 干扰治疗的最新进展。
Neurotherapeutics. 2013 Jul;10(3):473-85. doi: 10.1007/s13311-013-0183-8.
2
Development of microRNA-based therapeutics for central nervous system diseases.基于 microRNA 的中枢神经系统疾病治疗药物的研发。
Eur J Pharmacol. 2023 Oct 5;956:175956. doi: 10.1016/j.ejphar.2023.175956. Epub 2023 Aug 2.
3
RNAi therapeutics for CNS disorders.中枢神经系统疾病的 RNAi 治疗。
Brain Res. 2010 Jun 18;1338:112-21. doi: 10.1016/j.brainres.2010.03.038. Epub 2010 Mar 20.
4
Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.显性遗传神经退行性疾病的基因抑制策略：来自亨廷顿舞蹈症和脊髓小脑共济失调的经验教训
Hum Mol Genet. 2016 Apr 15;25(R1):R53-64. doi: 10.1093/hmg/ddv442. Epub 2015 Oct 26.
5
Use of gene therapy in central nervous system repair.基因疗法在中枢神经系统修复中的应用。
Acta Neurol Scand. 2004 Jan;109(1):1-8. doi: 10.1046/j.1600-0404.2003.00240.x.
6
The emerging therapeutic role of RNA interference in disorders of the central nervous system.RNA干扰在中枢神经系统疾病中的新兴治疗作用。
Clin Pharmacol Ther. 2011 Mar;89(3):450-4. doi: 10.1038/clpt.2010.312. Epub 2011 Jan 19.
7
RNA-based therapeutics for neurological diseases.基于 RNA 的神经疾病治疗方法。
RNA Biol. 2022;19(1):176-190. doi: 10.1080/15476286.2021.2021650. Epub 2021 Dec 31.
8
Harnessing RNA interference to develop neonatal therapies: from Nobel Prize winning discovery to proof of concept clinical trials.利用 RNA 干扰开发新生儿疗法：从诺贝尔奖获奖发现到概念验证临床试验。
Early Hum Dev. 2009 Oct;85(10 Suppl):S31-5. doi: 10.1016/j.earlhumdev.2009.08.013. Epub 2009 Oct 14.
9
Advances in the Design of (Nano)Formulations for Delivery of Antisense Oligonucleotides and Small Interfering RNA: Focus on the Central Nervous System.用于递送反义寡核苷酸和小干扰 RNA 的（纳米）制剂设计的进展：聚焦于中枢神经系统。
Mol Pharm. 2021 Apr 5;18(4):1491-1506. doi: 10.1021/acs.molpharmaceut.0c01238. Epub 2021 Mar 18.
10
Delivery of siRNA into the blood-brain barrier: recent advances and future perspective.小干扰RNA递送至血脑屏障：最新进展与未来展望
Ther Deliv. 2012 Apr;3(4):417-20. doi: 10.4155/tde.12.22.
引用本文的文献
1
CNS Delivery of Nucleic Acid Therapeutics: Beyond the Blood-Brain Barrier and Towards Specific Cellular Targeting.中枢神经系统递药：超越血脑屏障和迈向特定细胞靶向。
Pharm Res. 2023 Jan;40(1):77-105. doi: 10.1007/s11095-022-03433-5. Epub 2022 Nov 15.
2
Small interfering RNAs based therapies for intracerebral hemorrhage: challenges and progress in drug delivery systems.基于小干扰RNA的脑出血治疗：药物递送系统的挑战与进展
Neural Regen Res. 2022 Aug;17(8):1717-1725. doi: 10.4103/1673-5374.332129.
3
Non-viral Vector Mediated RNA Interference Technology for Central Nerve System Injury.非病毒载体介导的RNA干扰技术用于中枢神经系统损伤
DNA RNA Nanotechnol. 2016;3(1):14-22. doi: 10.1515/rnan-2016-0003. Epub 2016 Aug 25.
4
IGFBP‑rP1‑silencing promotes hypoxia‑induced angiogenic potential of choroidal endothelial cells via the RAF/MEK/ERK signaling pathway.IGFBP-rP1-沉默通过 RAF/MEK/ERK 信号通路促进脉络膜内皮细胞的缺氧诱导的血管生成潜能。
Mol Med Rep. 2020 Dec;22(6):4837-4847. doi: 10.3892/mmr.2020.11578. Epub 2020 Oct 11.
5
Oligonucleotide therapeutics in neurodegenerative diseases.神经退行性疾病的寡核苷酸治疗。
RNA Biol. 2018;15(6):707-714. doi: 10.1080/15476286.2018.1454812. Epub 2018 Jun 1.
6
Gene suppression strategies for dominantly inherited neurodegenerative diseases: lessons from Huntington's disease and spinocerebellar ataxia.显性遗传神经退行性疾病的基因抑制策略：来自亨廷顿舞蹈症和脊髓小脑共济失调的经验教训
Hum Mol Genet. 2016 Apr 15;25(R1):R53-64. doi: 10.1093/hmg/ddv442. Epub 2015 Oct 26.
7
A brief perspective on neural cell therapy.神经细胞治疗的简要概述。
Mol Cell Ther. 2014 Jan 8;2:2. doi: 10.1186/2052-8426-2-2. eCollection 2014.
8
Inducible and combinatorial gene manipulation in mouse brain.小鼠大脑中的可诱导和组合式基因操纵
Front Cell Neurosci. 2015 Apr 21;9:142. doi: 10.3389/fncel.2015.00142. eCollection 2015.
9
The role of the immune system in triplet repeat expansion diseases.免疫系统在三核苷酸重复扩增疾病中的作用。
Mediators Inflamm. 2015;2015:873860. doi: 10.1155/2015/873860. Epub 2015 Mar 22.
10
Mechanisms of RNA-induced toxicity in CAG repeat disorders.CAG 重复疾病中 RNA 诱导毒性的机制。
Cell Death Dis. 2013 Aug 1;4(8):e752. doi: 10.1038/cddis.2013.276.
本文引用的文献
1
Engineering and Selection of Shuffled AAV Genomes: A New Strategy for Producing Targeted Biological Nanoparticles.改组腺相关病毒基因组的工程设计与筛选：一种生产靶向生物纳米颗粒的新策略。
Mol Ther. 2008 Jul;16(7):1252-1260. doi: 10.1038/mt.2008.100. Epub 2016 Dec 8.
2
Global CNS gene delivery and evasion of anti-AAV-neutralizing antibodies by intrathecal AAV administration in non-human primates.鞘内注射 AAV 实现全球中枢神经系统基因传递和逃避抗 AAV 中和抗体。
Gene Ther. 2013 Apr;20(4):450-9. doi: 10.1038/gt.2012.101. Epub 2013 Jan 10.
3
Designing functional siRNA with reduced off-target effects.设计具有降低脱靶效应的功能性小干扰RNA。
Methods Mol Biol. 2013;942:57-68. doi: 10.1007/978-1-62703-119-6_3.
4
Chronic suppression of inositol 1,4,5-triphosphate receptor-mediated calcium signaling in cerebellar purkinje cells alleviates pathological phenotype in spinocerebellar ataxia 2 mice.小脑浦肯野细胞中肌醇 1,4,5-三磷酸受体介导的钙信号慢性抑制可减轻脊髓小脑共济失调 2 型小鼠的病理表型。
J Neurosci. 2012 Sep 12;32(37):12786-96. doi: 10.1523/JNEUROSCI.1643-12.2012.
5
Displaying high-affinity ligands on adeno-associated viral vectors enables tumor cell-specific and safe gene transfer.将高亲和力配体展示在腺相关病毒载体上，可实现肿瘤细胞特异性和安全的基因转移。
Mol Ther. 2013 Jan;21(1):109-18. doi: 10.1038/mt.2012.186. Epub 2012 Sep 11.
6
siSPOTR: a tool for designing highly specific and potent siRNAs for human and mouse.siSPOTR：一种用于设计针对人和小鼠的高度特异性和有效 siRNA 的工具。
Nucleic Acids Res. 2013 Jan 7;41(1):e9. doi: 10.1093/nar/gks797. Epub 2012 Aug 31.
7
Single-stranded RNAs use RNAi to potently and allele-selectively inhibit mutant huntingtin expression.单链 RNA 通过 RNAi 强效且等位基因选择性地抑制突变型亨廷顿蛋白的表达。
Cell. 2012 Aug 31;150(5):895-908. doi: 10.1016/j.cell.2012.08.002.
8
Single-stranded siRNAs activate RNAi in animals.单链 siRNAs 在动物中激活 RNAi。
Cell. 2012 Aug 31;150(5):883-94. doi: 10.1016/j.cell.2012.08.014.
9
Singles engage the RNA interference pathway.单链 RNA 激活 RNA 干扰途径。
Cell. 2012 Aug 31;150(5):873-5. doi: 10.1016/j.cell.2012.08.008.
10
Silencing of Parkinson's disease-associated genes with artificial mirtron mimics of miR-1224.利用 miR-1224 的人工 mirtron 模拟物沉默帕金森病相关基因。
Nucleic Acids Res. 2012 Oct;40(19):9863-75. doi: 10.1093/nar/gks712. Epub 2012 Jul 30.
Zotero 插件